Protonix Interactions Checker – Drugs.com

Print

Save

There are 163 drugs known to interact with
Protonix (pantoprazole), along with
4 disease interactions.

Of the total drug interactions,
16 are major, 128 are moderate, and 19 are minor.

Does Protonix interact with my other drugs?

Enter other medications to view a detailed report.

• View all 163 medications that may interact with Protonix
• View Protonix disease interactions (4)

Most frequently checked interactions

View interaction reports for Protonix (pantoprazole) and the medicines listed below.

• Major
• Moderate
• Minor
• Unknown

• albuterol
• amlodipine
• aspirin
• atorvastatin
• Cymbalta (duloxetine)
• folic acid
• gabapentin
• Lasix (furosemide)
• levothyroxine
• Lexapro (escitalopram)
• Lipitor (atorvastatin)
• lisinopril
• losartan
• Lyrica (pregabalin)
• metformin
• metoprolol
• Plavix (clopidogrel)
• potassium chloride
• prednisone
• Singulair (montelukast)
• Synthroid (levothyroxine)
• tramadol
• trazodone
• Tylenol (acetaminophen)
• Vitamin B12 (cyanocobalamin)
• Vitamin D3 (cholecalciferol)
• Xanax (alprazolam)
• Zofran (ondansetron)
• Zoloft (sertraline)
• Zyrtec (cetirizine)

Protonix disease interactions

There are 4 disease interactions with Protonix (pantoprazole) which include:

• C. diff
• liver disease
• bone fractures
• hypomagnesemia

Report options

Loading…

QR code containing a link to this page

More about Protonix (pantoprazole)

• Protonix consumer information
• Compare alternatives
• Pricing & coupons
• Reviews (80)
• Drug images
• Side effects
• Dosage information
• Patient tips
• During pregnancy
• Generic availability
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Duodenal Ulcer
• GERD

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.

Major	Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate	Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor	Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown	No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Protonix Reviews & Ratings – Drugs.com

Print

Save

Protonix
has an average rating of 7.1 out of 10 from a total of 78 reviews
on Drugs. com.
64% of reviewers reported a positive experience, while 23% reported a negative experience.

Reviews for Protonix

Frequently asked questions

• Pantoprazole vs. omeprazole: What’s the difference between them?
• Can you take pantoprazole 40 mg twice a day?
• What are the risks associated with heartburn medications?
• How long can I take pantoprazole?

Are you taking this medicine?

• Add your review
• Learn more about Protonix

More FAQ

• Does pantoprazole cause bloating?

Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.

More about Protonix (pantoprazole)

• Check interactions
• Compare alternatives
• Pricing & coupons
• Drug images
• Side effects
• Dosage information
• Patient tips
• During pregnancy
• Generic availability
• Support group
• Drug class: proton pump inhibitors
• Breastfeeding
• En español

Patient resources

• Drug Information
• Protonix oral/injection
• Protonix (Pantoprazole Intravenous) (Advanced Reading)
• Protonix (Pantoprazole Oral) (Advanced Reading)
• Protonix (Pantoprazole Delayed-Release Granules)
• Protonix (Pantoprazole Delayed-Release Tablets)

Professional resources

• Prescribing Information

Other formulations

• Protonix IV

Related treatment guides

• Erosive Esophagitis
• Barrett’s Esophagus
• Duodenal Ulcer
• GERD

Protonix Tablet English – Product

Protonix Tablet English – Product – TabletWise. com

About Us

• About Us
• Privacy Policy
• Instructions for Use

• Overview
• Benefits
• Side Effects
• Precautions

900 06 Interaction

• Contraindications

Overview

Protonix Tablet is used for Gastroesophageal reflux disease and other conditions.

Protonix Tablet contains Pantoprazole Sodium as an active ingredient. Available in tablet form.

Detailed information regarding the use, composition, dosage, side effects of Protonix Tablet / Protonix Tablet, as well as user reviews are provided below:

Uses

Protonix Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms: 4

Side-effects

The following is a list of possible side-effects that may occur from all constituents of Protonix Tablet. This list is not final. These side effects have been recorded previously, but are not always recorded when using the drug. Some of these side effects may be extremely rare, but have incredibly severe consequences. If you notice any side effects, contact your doctor immediately. Especially in the case of observing side effects for a long time.

• Constipation
• Headache
• Nausea
• Vomiting
• Gas
• Joint pain
• Constipation

90 003 If you experience side effects not listed above, contact your healthcare provider for advice. In addition, you can report side effects to your local Food and Drug Administration.

Precautions

Before starting this drug, tell your doctor about any medications you are taking, nutritional supplements (eg vitamins, natural supplements, etc.), allergies, existing medical conditions, and current health conditions (eg, pregnancy, upcoming surgery, etc. ). The side effects of the drug may be more pronounced depending on the condition of your body. Take this medicine as directed by your doctor, or follow the directions for use that come with your medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or if your condition worsens. Important points to discuss with your healthcare provider are listed below.

• Breastfeeding
• Low blood magnesium
• Plan to get pregnant
• pregnant

Tablet / Protonix Tablet is subject to change. Tell your healthcare provider about all medications, vitamins, and supplements you use. Your doctor will be able to make the right plan for taking the drug, which will avoid negative interactions. Protonix Tablet may interact with the following drugs and products:

• Ampicillin
• Atazanavir
• Dexlansoprazole
• Digoxin
• Esomeprazole
• Ketoconazole
• Lansoprazole 90 008
• Methotrexate
• Nelfinavir
• Omeprazole

Hypersensitivity to Protonix Tablet is a contraindication. In addition, Protonix Tablet should not be used if you have the following conditions:

• Allergic reaction

Composition and active ingredients

Protonix Tablet is composed of the following active ingredients (salts)

• Pantoprazole Sodium attention to the fact that this drug is available with different strengths of intensity for each of the active ingredients listed above.

  Packing Options and Strengths

  Protonix Tablet is available in the following packages and strengths

  Protonix Tablet packages available: EQ 40MG BASE, EQ 20MG BASE

  FAQ

  • Is it safe to drive or operate heavy machinery while using this product?

    If you experience drowsiness, dizziness, hypotension or a headache as side-effects when using Protonix Tablet medicine then it may not be safe to drive a vehicle or operate heavy machinery. You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Protonix Tablet. Be sure to consult your doctor for advice based on the characteristics of your body and general health.

  • Is this drug (product) addictive or addictive?

    Most drugs are not habit-forming or addictive. In most cases, the state classifies drugs that can be addictive as controlled dispensing drugs. For example, schedule H or X in India and schedule II-V in the USA. Please check the information on the drug packaging to make sure that this drug is not in the controlled category. Also, do not self-medicate or accustom your body to medications without consulting your doctor.

  • Can I stop using this product immediately or do I need to slowly stop using it?

    Some medications need to be stopped gradually due to a rebound effect. Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.

  Cite this page

  Page URL

  HTML Link

  Protonix Tablet

  APA Style Citation

  • Protonix Tablet – Product – TabletWise.com. (n.d.). Retrieved May 03, 2023, from https://www.tabletwise.com/us-ru/protonix-tablet

  MLA Style Citation

  • “Protonix Tablet in English – Product – TabletWise.com” Tabletwise.com . N.p., n.d. Web. May 03 2023.

  Chicago Style Citation

  • “Protonix Tablet in English – Product – TabletWise.com” Tabletwise. Accessed May 03, 2023. https://www.tabletwise.com/us-ru/protonix-tablet.

  More information about Protonix Tablet

  • Uses of
  • Reviews
  • What are the uses of Protonix Tablet?
  • What are the side effects of Protonix Tablet?
  • What other medicines does Protonix Tablet interact with?
  • When should you not use Protonix Tablet?
  • What precautions should you take while using Protonix Tablet?

  Last updated date

  This page was updated on 9/28/2020.

  This page provides information for Protonix Tablet Product in English .

  Share with friends, get 20% off

  Invite your friends to TabletWise learning marketplace. For each purchase they make, you get 20% off (upto $10) on your next purchase.

  Protonix I.V. – instructions for use, dosage, composition, analogs, side effects / Pillintrip

  WARNINGS

  Included as part of PRECAUTIONS section.

  PRECAUTIONS

  Sequelae of symptomatic response

  Symptomatic response to pantoprazole therapy does
  does not exclude the presence of malignant neoplasms of the stomach.

  Hypersensitivity and severe skin reactions

  Anaphylaxis and other serious reactions such as erythema
  multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis (TEN) have
  reported with the use of intravenous pantoprazole. It may require an emergency
  treatment .

  Injection site reactions

  Thrombophlebitis has been associated with administration
  intravenous pantoprazole.

  Potential for worsening zinc deficiency

  PROTONIX contains disodium edetate (salt form
  EDTA), a chelator of metal ions, including zinc. Therefore, zinc supplements
  should be considered in patients treated with PROTONIX I.V. for injection who
  susceptible to zinc deficiency. Caution should be exercised when using other EDTA-containing
  products are also administered intravenously.

  Clostridium Difficile associated diarrhea

  Published observational studies show that PPI therapy
  how PROTONIX may be associated with increased risk Clostridium
  difficile associated diarrhea, especially in hospitalized patients. This
  the diagnosis should be considered in diarrhea that does not improve.

  Patients should use the lowest dose and shortest duration
  PPI therapy appropriate to the condition being treated.

  Broken bones

  Several published observational studies suggest this
  proton pump inhibitor (PPI) therapy may be associated with an increased risk
  with fractures of the hip, wrist or spine associated with osteoporosis. Risk
  the fracture was enlarged in patients treated with a high dose, defined as multiple
  daily doses and long-term PPI therapy (a year or more). Patients should use
  lowest dose and shortest duration of PPI therapy consistent with
  the condition is being treated. Patients at risk of fractures associated with osteoporosis
  should be administered in accordance with established treatment guidelines.

  Hepatic effects

  Mild, transient increases in transaminases have been
  observed in clinical studies. The clinical significance of this discovery in
  the large population of subjects receiving intravenous pantoprazole is unknown. .

  Hypomagnesemia

  Hypomagnesemia, symptomatic and asymptomatic, was
  rarely reported in patients treated with PPIs for at least three months, and in
  most cases after a year of therapy. Serious adverse events include tetany
  arrhythmias and seizures. In most patients, treatment of hypomagnesaemia
  necessary replacement of magnesium and discontinuation of PPI

  For patients who are expected to be on long-term treatment or who
  take PPIs with drugs such as digoxin or drugs that can cause
  hypomagnesemia (eg. , diuretics), healthcare professionals may consider
  monitoring magnesium levels prior to initiating PPI treatment, and
  periodically.

  THC Urine Screen Interference

  Can produce THC false positive urinalysis
  (tetrahydrocannabinol)

  .

  Simultaneous use of protonix with methotrexate

  Literature suggests that concomitant use of PPIs with
  methotrexate (mainly at high doses;

  Preclinical toxicology

  Carcinogenesis, mutagenesis, impaired fertility

  In a 24-month Sprague-Dawley rat carcinogenicity study
  treated orally with doses of 0.5 to 200 mg/kg/day, about 0.1 to 40 times
  an effect on the body surface area of ​​a 50 kg human administered a dose of 40 mg/day.
  In the gastric fund, treatment is performed at a dose of 0.5 to 200 mg / kg / day
  enterochromaffin-like (ECL) cell hyperplasia and benign and malignant
  neuroendocrine cell tumors in a dose-dependent manner. In the forest stomach
  treatment at a dose of 50 and 200 mg / kg / day (about 10 and 40 times the recommended person
  dose based on body surface area) caused benign squamous papillomas and
  malignant squamous cell carcinomas. Rare gastrointestinal tumors are associated
  with pantoprazole treatment included duodenal adenocarcinoma at age 50
  mg / kg / day and benign polyps and adenocarcinomas of the gastric fund in 200
  mg/kg/day. The liver is treated at a dose of 0.5 to 200 mg/kg/day
  dose escalation for hepatocellular adenomas and related doses
  carcinomas. In the thyroid gland, treatment at a dose of 200 mg / kg / day increased
  frequency of follicular cell adenomas and carcinomas in both men and women
  rats.

  In a 24-month Fischer rat carcinogenicity study 344
  treated orally with doses of 5 to 50 mg/kg/day, about 1 to 10
  multiply the recommended human dose based on body surface area. in the stomach
  Fundus, treated at a dose of 5 to 50 mg/kg/day, produces enterochromaffin-like (ECL)
  cell hyperplasia; and benign and malignant neuroendocrine cell tumors. Dose
  selection for this study may not have been sufficient for a comprehensive assessment
  carcinogenic potential of pantoprazole.

  In a 24-month carcinogenicity study in B6C3F1 mice,
  orally treated with doses of 5 to 150 mg/kg/day, 0. 5 to 15 times more
  recommended human dose based on body surface area. In the liver treatment at 150
  mg/kg/day caused an increase in the frequency of hepatocellular adenomas and
  carcinomas in female mice. Treatment of 5 to 150 mg/kg/day is also done
  hyperplasia of ECL cells of the stomach.

  26-week Carcinogenicity Study in Transgenic Mice
  was not positive.

  Pantoprazole was positive in in vitro people
  lymphocyte chromosomal aberration assays in one of two mouse micronuclei
  tests for clastogenic effects and in vitro Chinese hamster ovary
  direct cell mutation/HGPRT assay for mutagenic effects. Equivalent results were
  observed in an in vivo rat liver DNA covalent binding assay. Pantoprazole was
  negative in in vitro Ames mutation assay in vitro unscheduled DNA
  synthesis assay (UDS) with rat hepatocytes, in vitro AS52 / GPT mammal
  gene mutation assay in cell direction in vitro thymidine kinase mutation test
  with L5178Y mouse lymphoma cells and rat bone marrow cell in vivo
  analysis of chromosomal aberration.

  No effect on fertility or reproduction
  performance when taking pantoprazole at oral doses up to 500 mg/kg/day
  male rats (98 times the recommended human dose based on body surface area) and
  450 mg/kg/day in female rats (88 times the recommended human dose depending on the body
  surface area).

  Use in certain populations

  Pregnancy

  Teratogenic effects – Pregnancy category B

  Reproduction studies have been performed in rats in
  intravenous doses up to 20 mg/kg/day (4 times the recommended human dose
  on the body surface) and rabbits at intravenous doses up to 15 mg/kg/day (6
  times the recommended human dose depending on body surface area) and identified
  there is no evidence of impaired fertility or harm to the fetus due to pantoprazole. There
  however, there are no adequate and well-controlled studies in pregnant women.
  Because animal reproduction studies don’t always predict humans
  In response, this medication should be used during pregnancy only if clearly needed.

  Nursing mothers

  Pantoprazole and its metabolites are excreted in milk
  rats. Excretion of pantoprazole in breast milk was found in a study a
  single mother after a single dose of 40 mg. Clinical relevance
  this find is unknown. Many drugs that are excreted in breast milk have
  potential for serious adverse reactions in infants. Based
  carcinogenic potential shown for pantoprazole in rodent carcinogenicity
  research, a decision must be made whether to terminate care or
  stop taking the drug, taking into account the benefits of the drug for
  Mother.

  Pediatric use

  Safety and efficacy of PROTONIX I.V. in pediatric
  patients were not created.

  Geriatric use

  No age difference in safety profile
  intravenous pantoprazole has been seen in international trials involving 86 elderly people
  (≥ 65 years) and 200 young (<65 years) patients with erosive esophagitis associated with GERD. The frequency of healing of esophagitis in 107 elderly patients (≥ 65 years) treated with oral pantoprazole in the US, clinical trials were similar to those found in patients under that age out of 65.